Form 4: CG Oncology Director Leonard Post Executes Stock Option and Sells Shares

CG Oncology director Leonard Post exercised stock options and sold 1,000 shares of common stock on January 13, 2025, according to a recent SEC filing.

Summary

• Leonard Post, a director at CG Oncology, exercised a stock option to acquire 1,000 shares of common stock at a price of $0.60 per share on January 13, 2025.
• On the same day, Mr. Post sold 1,000 shares of common stock at a price of $29.66 per share.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 6, 2024.
• Following these transactions, Mr. Post directly owns 0 shares of common stock.
• Mr. Post also holds 132,077 derivative securities in the form of director stock options.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing a stock transaction by a director. It doesn't indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the transactions of company directors and officers.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan is a common practice among corporate insiders to avoid accusations of insider trading.
• The reported transactions are typical for directors who receive stock options as part of their compensation.

Stakeholder Impact

• The transactions have a minimal impact on stakeholders as they are part of a pre-planned trading strategy.

Key Dates

Keywords

CG Oncology, stock options, insider trading, SEC Form 4, Rule 10b5-1, stock sale, director, Leonard Post